Online inquiry

IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2726MR)

This product GTTS-WQ2726MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL23A gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_016584.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51561
UniProt ID Q9NPF7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2726MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4311MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BIVV009
GTTS-WQ438MR IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 3C23K
GTTS-WQ872MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-176
GTTS-WQ13756MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN 1500
GTTS-WQ5107MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Campath-1H
GTTS-WQ7523MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GC-182
GTTS-WQ7471MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GBR-830
GTTS-WQ12316MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MT203
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW